Comparing the current results to its competitors, Lucid Diagnostics Inc reported Revenue increase in the 1 quarter 2026 by 51.69 % year on year. The sales growth was above Lucid Diagnostics Inc 's competitors' average revenue growth of 4.84 %, achieved in the same quarter.
Lucid Diagnostics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 5.82 %
Lucid Diagnostics Inc 's Comment on Competition and Industry Peers
The company operates in the U.S. market for esophageal adenocarcinoma (EAC) and pre-cancer testing, competing with procedure-based detection technologies such as upper endoscopy and various testing methods, including assays that incorporate biomarker multi-cancer early detection products. Its EsoGuard test competes with these technologies. The EsoCheck device competes with other manufacturers' devices designed to collect cell samples from targeted regions of the esophagus. One competitor device is EndoSign, commercialized by Cyted, which uses a small mesh sponge within a soluble gelatin capsule that dissolves in the stomach and is then pulled through the esophagus to collect samples. Unlike EsoCheck, EndoSign is unprotected from sample contamination as it passes through the upper esophagus and mouth. The company is also aware of other companies developing additional methods for detecting esophageal cancer and pre-cancer that have not yet been announced. Additionally, competition exists in recruiting and retaining qualified personnel and acquiring complementary technologies and licenses. To compete effectively, the company's products must achieve market acceptance, receive adequate insurance coverage and reimbursement, be cost-effective, and be safe and effective.
Livanova Plc is a global medical technology company that focuses on developing and delivering innovative solutions for patients with cardiovascular diseases and neuropsychiatric disorders. Through their diverse portfolio, they offer products and therapies that encompass surgical heart valves, cardiac rhythm management, and neuromodulation. Livanova adopts a patient-centric approach, collaborating with healthcare professionals to improve patient outcomes and enhance quality of life.
Ir med Inc's business model involves providing innovative medical technologies and solutions to the healthcare industry. The company focuses on developing and commercializing advanced medical devices that aim to improve patient outcomes and enhance overall healthcare management.
Iridex Corp's business model revolves around providing advanced medical devices and solutions for the treatment of eye conditions, primarily focused on ophthalmology.
Illumina Inc is a leading company in the genomics sector, focusing on next-generation sequencing technologies that enhance genetic analysis. Their business model encompasses a diverse range of products, including sequencing platforms, reagents, and bioinformatics solutions, which together facilitate comprehensive genomic studies for researchers. By integrating these tools, Illumina supports advancements in fields such as oncology, drug discovery, and personalized healthcare, positioning itself at the forefront of genomic innovation.
Sources:
Lucid Diagnostics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Lucid Diagnostics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
